The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.

Click to increase image sizeClick to decrease image size AcknowledgementsWe acknowledge that the Leukemia and Lymphoma Society Registry is supported by BeiGene, Pharmacyclics, an AbbVie Company, Kite, a Gilead Company, and Janssen Biotech.Disclosure statementNo potential conflict of interest was reported by the author(s).Author contributorsL.M.G. and L.A.S. designed and conducted the survey and participated in data collection. L.G., A.N., E.L., and V.S. performed the analysis. A.N. and E.L. wrote the manuscript. All authors provided critical feedback and reviewed the final manuscript. A.N. – Grant/Research: Pharmacyclics/AbbVie; Kite/Gilead, Cornerstone. Consultant: Janssen, Morphosys, Cornerstone, Epizyme, EUSA, Recordati, TG therapeutics, ADC therapeutics, AstraZeneca, Kite/Gilead, Honoraria: Pharmacyclics/AbbVie.Additional informationFundingThis study was supported by the Leukemia and Lymphoma Society.